Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

2026-02-17 - 22:36

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate. Telix has been preparing the European and U.S. regulatory packages for TLX101-Px concurrently, bringing forward